NASDAQ: ARTVArtiva Biotherapeutics Inc Stock
$2.40+0.16 (+7.14%)
Updated Apr 21, 2025
ARTV Price
$2.40
Fair Value Price
$1.96
Market Cap
$58.47M
52 Week Low
$1.78
52 Week High
$17.31
P/E
-0.41x
P/B
0.31x
P/S
452.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$251.00k
Earnings
-$65.37M
Gross Margin
100%
Operating Margin
-26,045.02%
Profit Margin
-26,045%
Debt to Equity
0.12
Operating Cash Flow
-$55M
Beta
1.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ARTV Overview
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARTV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ARTV
Ranked#109 of 462
Ranked#109 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important ARTV news, forecast changes, insider trades & much more!
ARTV News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARTV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARTV ($2.40) is overvalued by 22.35% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARTV ($2.40) is not significantly undervalued (22.35%) relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARTV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARTV due diligence checks available for Premium users.
Valuation
ARTV fair value
Fair Value of ARTV stock based on Discounted Cash Flow (DCF)
Price
$2.40
Fair Value
$1.96
Overvalued by
22.35%
ARTV ($2.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARTV ($2.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARTV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ARTV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
-184.27x
Market
27.14x
ARTV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
4.04x
ARTV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARTV's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.1M
Profit Margin
0%
ARTV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARTV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$209.6M
Liabilities
$22.9M
Debt to equity
0.12
ARTV's short-term assets ($188.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARTV's short-term assets ($188.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARTV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.7M
Investing
-$966.0k
Financing
-$30.0k
ARTV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARTV vs Biotech Stocks
Artiva Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.